CDMO

ANALYST NOTE: AVID BIOSERVICES, INC. (CDMO) DATE: 2026-06-13 CURRENT PRICE: $12.49

1. Structural Readiness

State: Context-Only Conservative Entry: — Breakout Level: — Extension: — ATR at Breakout: — ATR Current: 0.4% (Sub-threshold)

Structural Assessment:

2. Thesis Layer

Thesis Classification: Tactical / Setup-Led Secular Exposure: None Named

At this date, there is no named secular thesis attached to Avid Bioservices. This is a tactical, setup-led name. The investment case must be judged strictly on the quality of the technical setup (which is currently undefined) and the underlying business fundamentals. No macro or industry-wide secular tailwinds are explicitly named in the evidence base to serve as a conviction anchor. The analysis relies entirely on the company's operational execution and the potential for a structural breakout to form in the future.

3. Business Overview

Company Profile: Avid Bioservices, Inc. operates as a Contract Development and Manufacturing Organization (CDMO) specializing in the development and CGMP-compliant production of biopharmaceutical drug substances. The company's core expertise lies in compounds derived from mammalian cell culture, providing both clinical and commercial scale manufacturing solutions. Beyond manufacturing, the company offers process development services (upstream/downstream optimization), bulk packaging, release and stability testing, and regulatory submission support. The primary client base consists of biotechnology and biopharmaceutical firms.

Operational Evidence (Source Date: 2024-09-09):

• Backlog & Wins: In Q1 Fiscal 2025, the company signed $66 million in net new project agreements, ending the quarter with a record-high backlog of $219 million. These net new wins represented the highest volume since Q3 Fiscal 2023.
• Customer Mix: A significant majority of new signings involved new customers, including the addition of another large pharma customer. The portfolio includes a mix of early and late-stage programs, though the company remains weighted toward late-stage.
• Program Stage: Two of the newest Process Development and Quality (PPQ) programs are noted: one is a Phase 3 program advancing toward commercialization, and the other is a commercially approved product currently on the market.
• Financial Performance: Q1 Fiscal 2025 revenues were $40.2 million, a 6% increase year-over-year from $37.7 million. Gross profit improved to $5.7 million (14% gross margin) compared to $4.1 million (11% gross margin) in the prior year period.
• Management Expectations: Management stated that PPQ programs are "particularly attractive" as they are a pre-commercialization requirement. They cautioned that execution of a PPQ campaign is the beginning of a one to two-year journey toward potential commercial approval and subsequent manufacture. Management expects these programs to drive increases in revenues, capacity utilization, and margins over that horizon.

4. Archetype and Conviction

Archetype: Growth Leader Rationale: The company fits the "Growth Leader" archetype based on the record-high backlog ($219M), the highest net new wins since 2023, and the expansion of gross margins (11% to 14%). The shift toward late-stage and PPQ programs aligns with a growth trajectory where revenue visibility increases as programs approach commercialization.

Valuation & Financial Context:

• Forward Consensus: The financial spine indicates a Forward Consensus EPS of -0.11333 for FY1 and 0.18 for FY2.
• Conviction Stack:
• *Thesis Strength:* Low (No named secular thesis; purely tactical).
• *Evidence Quality:* Moderate (Strong operational data from 2024, but financial spine shows near-term losses).
• *Setup Readiness:* None (Context-only).
• *Rerating Potential:* Dependent on the successful execution of the 1-2 year PPQ journey and the realization of the FY2 positive EPS.

5. Invalidations, Strengths, and Gaps

What Would Strengthen the Case:

• Margin Expansion: Continued gross margin expansion beyond the 14% reported in Q1 FY2025, validating the management expectation of margin improvement from PPQ programs.
• Backlog Conversion: Evidence of the $219M backlog converting to revenue faster than the 1-2 year PPQ timeline suggests.

What Would Invalidate the Case:

• Backlog Stagnation: A failure to sign new projects or a significant reduction in the backlog, contradicting the "record high" narrative.
• Margin Compression: A return to single-digit gross margins, suggesting an inability to scale efficiently.

Evidence Gaps:

• Recent Financials: The most recent earnings data is from September 2024 (Q1 FY2025). There is no evidence of Q2, Q3, or Q4 FY2025 results or Q1 FY2026 results as of the event date (2026-06-13).
• Current Volatility: The ATR of 0.4% is sub-threshold, making it difficult to assess the structural quality of any potential move without more recent price action data.

PRIVATE ANALYST CALL

Judgment: Hold Confidence: low Key evidence: Record backlog of $219M; Gross margin expansion to 14%; Net new wins of $66M in Q1 FY2025. Sizing hint: N/A (Setup not actionable) Expected path: Management expects a 1-2 year journey from PPQ to commercialization; revenue and margin growth expected to follow as programs advance. Expected horizon: 12-24 months for structural thesis to play out.